Payment overview · 2025
General Payments
$841.72
37 reported records · 17 companies
Healthcare provider profile · identity verified
Salil Kumar Trehan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · AMARILLO, TX · NPI 1194766121
Verified facts
What the public records show
CMS Open Payments records show Salil Kumar Trehan, M.D. received $841.72 in general payments during 2025 across 37 reported records.
Dexcom, Inc. accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Mounjaro, Nurtec Odt, Ozempic, Trelegy Ellipta, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Paxlovid by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Tymlos by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $114.75 | 13.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $108.36 | 12.9% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.54 | 11.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.78 | 8.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.98 | 8.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.17 | 7.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.92 | 6.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.90 | 5.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $43.38 | 5.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $39.75 | 4.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.81 | 2.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.29 | 2.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.09 | 2.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $19.91 | 2.4% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.56 | 2.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.42 | 1.9% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.11 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $841.72 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $114.75 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $114.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $108.36 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $73.78 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.98 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.92 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.92 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $56.23 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.04 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.67 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.90 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $43.38 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.75 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.81 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.29 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 209 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 17 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 162 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
73 | 21 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
209 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
162 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
37 | 37 |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
17 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1064 | 150 |
| Levothyroxine Sodium | Levothyroxine Sodium | 944 | 252 |
| Amlodipine Besylate | Amlodipine Besylate | 859 | 275 |
| Atorvastatin Calcium | Atorvastatin Calcium | 856 | 242 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 576 | 181 |
| Tramadol Hcl | Tramadol Hcl | 550 | 129 |
| Gabapentin | Gabapentin | 534 | 168 |
| Losartan Potassium | Losartan Potassium | 530 | 161 |
| Alprazolam | Alprazolam | 505 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 487 | 141 |
| Omeprazole | Omeprazole | 418 | 123 |
| Alendronate Sodium | Alendronate Sodium | 395 | 126 |
| Furosemide | Furosemide | 379 | 133 |
| Metformin Hcl | Metformin Hcl | 375 | 115 |
| Potassium Chloride | Potassium Chloride | 354 | 123 |
| Lisinopril | Lisinopril | 348 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 324 | 96 |
| Montelukast Sodium | Montelukast Sodium | 313 | 84 |
| Simvastatin | Simvastatin | 290 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 268 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 88 |
| Carvedilol | Carvedilol | 245 | 69 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 234 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 230 | 71 |
| Allopurinol | Allopurinol | 227 | 65 |
| Temazepam | Temazepam | 220 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 214 | 65 |
| Glimepiride | Glimepiride | 214 | 66 |
| Farxiga | Dapagliflozin Propanediol | 209 | 53 |
| Diazepam | Diazepam | 201 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 187 | 134 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 182 | 55 |
| Trazodone Hcl | Trazodone Hcl | 175 | 66 |
| Methocarbamol | Methocarbamol | 173 | 57 |
| Levofloxacin | Levofloxacin | 171 | 132 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 170 | 132 |
| Azithromycin | Azithromycin | 168 | 122 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 68 |
| Spironolactone | Spironolactone | 168 | 49 |
| Clonazepam | Clonazepam | 162 | 24 |
| Mounjaro | Tirzepatide | 162 | 30 |
| Ezetimibe | Ezetimibe | 157 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 157 | 48 |
| Meloxicam | Meloxicam | 152 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 37 |
| Donepezil Hcl | Donepezil Hcl | 149 | 53 |
| Sertraline Hcl | Sertraline Hcl | 146 | 44 |
| Mirtazapine | Mirtazapine | 143 | 51 |
| Estradiol | Estradiol | 134 | 36 |
| Lorazepam | Lorazepam | 134 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 133 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 38 |
| Bupropion Xl | Bupropion Hcl | 127 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 35 |
| Prednisone | Prednisone | 117 | 82 |
| Ondansetron Hcl | Ondansetron Hcl | 115 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 32 |
| Ozempic | Semaglutide | 112 | 30 |
| Glipizide Er | Glipizide | 110 | 37 |
| Eliquis | Apixaban | 109 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 30 |
| Clonidine Hcl | Clonidine Hcl | 108 | 40 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 30 |
| Finasteride | Finasteride | 97 | 27 |
| Jardiance | Empagliflozin | 97 | 22 |
| Methylprednisolone | Methylprednisolone | 97 | 79 |
| Metformin Hcl Er | Metformin Hcl | 96 | 31 |
| Topiramate | Topiramate | 91 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 75 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 89 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 87 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 28 |
| Aripiprazole | Aripiprazole | 83 | 30 |
| Synthroid | Levothyroxine Sodium | 73 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 23 |
| Atenolol | Atenolol | 71 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 70 | 20 |
| Celecoxib | Celecoxib | 67 | 23 |
| Famotidine | Famotidine | 66 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 44 |
| Pregabalin | Pregabalin | 64 | 24 |
| Fluconazole | Fluconazole | 60 | 40 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 13 |
| Myrbetriq | Mirabegron | 58 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 54 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 21 |
| Glipizide | Glipizide | 53 | 16 |
| Propranolol Hcl | Propranolol Hcl | 53 | 17 |
| Xarelto | Rivaroxaban | 51 | 16 |
| Fenofibrate | Fenofibrate | 50 | 14 |
| Fentanyl | Fentanyl | 49 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 47 | 16 |
| Buspirone Hcl | Buspirone Hcl | 46 | 15 |
| Ondansetron Odt | Ondansetron | 46 | 14 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 45 | suppressed |
| Linzess | Linaclotide | 44 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 11 |
| Hydrocortisone | Hydrocortisone | 42 | 14 |
| Memantine Hcl | Memantine Hcl | 41 | 14 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 37 | 37 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Repatha Sureclick | Evolocumab | 34 | 12 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 14 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 13 |
| Torsemide | Torsemide | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 19 |
| Primidone | Primidone | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 21 | 13 |
| Prolia | Denosumab | 21 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Gemtesa | Vibegron | 17 | 12 |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Modafinil | Modafinil | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Alprazolam Odt | Alprazolam | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Tymlos | Abaloparatide | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Procto-Med Hc | Hydrocortisone | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 12 | 12 |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Granisetron Hcl | Granisetron Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $841.72 · 37 records | Dexcom, Inc. | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, FARXIGA, GEMTESA, LEQVIO, LUMRYZ, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Tymlos, VOQUEZNA, VRAYLAR, ZAVZPRET, ZEPBOUND, ZORYVE | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error